Showing 321 - 340 results of 68,922 for search '(( 5 ((mg decrease) OR (a decrease)) ) OR ( 50 ((mean decrease) OR (we decrease)) ))', query time: 0.87s Refine Results
  1. 321
  2. 322
  3. 323

    Protocols. by Yoichiro Kitajima (4319455)

    Published 2022
    Subjects:
  4. 324
  5. 325
  6. 326
  7. 327
  8. 328
  9. 329
  10. 330
  11. 331
  12. 332

    Fig 3 - by Yan Shu (441370)

    Published 2022
    Subjects:
  13. 333

    Fig 4 - by Yan Shu (441370)

    Published 2022
    Subjects:
  14. 334

    Fig 2 - by Yan Shu (441370)

    Published 2022
    Subjects:
  15. 335
  16. 336
  17. 337

    Discovery of the Triazolo[1,5‑<i>a</i>]Pyrimidine-Based Derivative WS-898 as a Highly Efficacious and Orally Bioavailable ABCB1 Inhibitor Capable of Overcoming Multidrug Resistance... by Shuai Wang (109515)

    Published 2021
    “…Here, we reported our medicinal chemistry efforts that led to the discovery of the triazolo­[1,5-<i>a</i>]­pyrimidine derivative <b>WS-898</b> as a highly effective ABCB1 inhibitor capable of reversing paclitaxel (PTX) resistance in drug-resistant SW620/Ad300, KB-C2, and HEK293/ABCB1 cells (IC<sub>50</sub> = 5.0, 3.67, and 3.68 nM, respectively), more potent than verapamil and zosuquidar. …”
  18. 338

    Discovery of the Triazolo[1,5‑<i>a</i>]Pyrimidine-Based Derivative WS-898 as a Highly Efficacious and Orally Bioavailable ABCB1 Inhibitor Capable of Overcoming Multidrug Resistance... by Shuai Wang (109515)

    Published 2021
    “…Here, we reported our medicinal chemistry efforts that led to the discovery of the triazolo­[1,5-<i>a</i>]­pyrimidine derivative <b>WS-898</b> as a highly effective ABCB1 inhibitor capable of reversing paclitaxel (PTX) resistance in drug-resistant SW620/Ad300, KB-C2, and HEK293/ABCB1 cells (IC<sub>50</sub> = 5.0, 3.67, and 3.68 nM, respectively), more potent than verapamil and zosuquidar. …”
  19. 339
  20. 340

    Lipid profile is associated with decreased fatigue in individuals with progressive multiple sclerosis following a diet-based intervention: Results from a pilot study by Kelly Fellows Maxwell (6852752)

    Published 2019
    “…</p><p>Results</p><p>FSS scores decreased from a baseline of 5.51 (95% CI: 4.86, 6.16) to a mean of 3.03 (95% CI: 2.23, 3.82) at 12 months (p < 0.001). …”